Berenberg Rates ATAI Life Sciences Buy with $12 Target on Strong Pipeline

Berenberg maintains Buy rating on ATAI Life Sciences (ATAI) with $12 price target, citing exceptional progress, strong pipeline momentum, and upcoming Phase 3 trials for psychedelic treatments.